Cardiovascular events in patients taking varenicline: A case series from intensive postmarketing surveillance in New Zealand

Drug Safety

Volumn 35, Issue 1, 2012, Pages 33-43

  Harrison Woolrych, Mira ^a   Maggo, Simran ^b   Tan, Ming ^a   Savage, Ruth ^a,c   Ashton, Janelle ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cardiovascular disorders; Postmarketing surveillance; Varenicline

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; AMOXICILLIN; BENDROFLUMETHIAZIDE; CELECOXIB; CILAZAPRIL; CLOPIDOGREL; DOXAZOSIN; FELODIPINE; FLUOXETINE; HYDROCHLOROTHIAZIDE PLUS QUINAPRIL; METOPROLOL; NAPROXEN; NORTRIPTYLINE; PANTOPRAZOLE; POTASSIUM CHLORIDE; SIMVASTATIN; VARENICLINE;

ANEURYSM; ANGINA PECTORIS; ANGIOGRAPHY; ANKYLOSING SPONDYLITIS; AORTA ANEURYSM; AORTA STENOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL OCCLUSION; BORNHOLM DISEASE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHEST TIGHTNESS; CORONARY ARTERY SPASM; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EDEMA; EXERCISE TEST; FAINTNESS; FLUSHING; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART REINFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; HYPOTENSION; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MESENTERIC VEIN THROMBOSIS; NEW ZEALAND; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERICARDIAL EFFUSION; PERIPHERAL VASCULAR DISEASE; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; PULSE RATE; QT PROLONGATION; QUESTIONNAIRE; SHOCK; SIDE EFFECT; STROKE; SUBARACHNOID HEMORRHAGE; SUDDEN DEATH; SYNCOPE; TACHYCARDIA; THORAX PAIN; THROMBOEMBOLISM; THROMBOPHLEBITIS; TREATMENT OUTCOME; VALVULAR HEART DISEASE; VEIN THROMBOSIS;

ADULT; AGED; BENZAZEPINES; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; NICOTINIC AGONISTS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; QUESTIONNAIRES; QUINOXALINES; SMOKING CESSATION;

EID: 83055165655     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11597690-000000000-00000     Document Type: Article

References (47)

1. Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med 2008; 359 (19): 2018-24
2. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at a4b2 and a full agonist at a7 neuronal nicotinic receptors. Mol Pharmacol 2006; 70 (3): 801-5 (Pubitemid 44268437)
3. Roddy E. Bupropion and other non-nicotine pharmacotherapies. BMJ 2004; 328 (7438): 509-11
4. Tonstad S. Smoking cessation efficacy and safety of varenicline, an [alpha]4[beta]2 nicotinic receptor partial agonist. J Cardiovasc Nurs 2006; 21 (6): 433-6
5. Tonstad S, Rollema H. Varenicline in smoking cessation. Expert Rev Respir Med 2010; 4 (3): 291-9
6. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166 (15): 1571-7 (Pubitemid 44232364)
7. Tsai S-T, Cho H-J, Cheng H-S, et al. A randomized, placebocontrolled trial of varenicline, a selective [alpha]4[beta]2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007; 29 (6): 1027-39 (Pubitemid 47198884)
8. Williams KE, Reeves KR, Billing CB, et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007; 23 (4): 793-801 (Pubitemid 46646499)
9. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placeboand bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166 (15): 1561-8 (Pubitemid 44232363)
10. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008; 63 (8): 717-24
11. Hays JT, Ebbert JO, Sood A. Efficacy and safety of varenicline for smoking cessation.AmJMed 2008; 121 (4 Suppl. 1): S32-42 (Pubitemid 351380541)
12. Harrison-WoolrychM. Psychiatric reactions with varenicline: interim results from intensive monitoring in New Zealand. Prescriber Update 2009March 2011 [online]. Available from URL: URL: http://www.medsafe.govt.nz/profs/ PUArticles/Varenicline%20Interim%20Results-May09.htm [Accessed 2011 Jul 15]
13. Harrison-Woolrych M, Ashton J. Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand. Drug Saf 2011; 34 (9): 763-72
14. Pfizer. New Zealand data sheet for Champix. March 2011 [online]. Available from URL: http://www.medsafe. govt.nz/profs/datasheet/c/Champixtab.pdf [Accessed 2011 Jun 15]
15. Pfizer. Summary of product characteristics for Champix [online]. Available from URL: http://www.medicines.org. uk/emc/document.aspx?documentId= 19045 [Accessed 2011 Jun 15]
16. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121 (2): 221-9
17. FDA. Chantix (varenicline): label change-risk of certain cardiovascular adverse events [online]. Available fromURL: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm259469.htm [Accessed 2011 Jul 15]
18. Singh S, Loke YK, Spangler JG, et al. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011; 183 (12): 1359-66
19. Coulter DM. The New Zealand intensive medicines monitoring programme. Pharmacoepidemiol Drug Saf 1998; 7 (2): 79-90 (Pubitemid 28252981)
20. Harrison-Woolrych M, Coulter DM. PEM in New Zealand. In: Mann R, Andrews EB, editors. Pharmacovigilance. 2nd ed. Chichester: John Wiley and Sons Ltd, 2007: 313-28
21. Kunac DL, Harrison-Woolrych M, Tatley MV. Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use. N Z Med J 2008; 121 (1283): 76-89
22. Edwards IR,Aronson JK. Adverse drug reactions: definitions, diagnosis, andmanagement. Lancet 2000; 356 (9237): 1255-9
23. Karch FE, Lasagna L. Adverse drug reactions: a critical review. JAMA 1975; 234 (12): 1236-41
24. Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis 2009; 205 (1): 23-32
25. New Zealand Guidelines Group. The assessment and management of cardiovascular risk. Wellington: New Zealand Guidelines Group, 2006: 26
26. Shakir SA. PEM in the UK. In: Mann R, Andrews EB, editors. Pharmacovigilance. 2nd ed. Chichester: John Wiley and Sons, 2007: 307-16
27. Institute for Safe Medication Practices. Strong safety signal seen for new varenicline risks [online]. Available from URL: http://www.ismp.org/docs/ vareniclinestudy.asp [Accessed 2011 Jul 15]
28. Nawrot TS, Perez L, Künzli N, et al. Public health importance of triggers of myocardial infarction: a comparative risk assessment. Lancet 2011; 377 (9767): 732-40
29. Prinzmetal M, Kennamer R, Merliss R, et al. Angina pectoris: I. A variant form of angina pectoris: preliminary report. Am J Med 1959; 27: 375-88
30. Myerburg RJ, Kessler KM, Mallon SM, et al. Lifethreatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary artery spasm. N Engl J Med 1992; 326 (22): 1451-5
31. Chevalier P, Dacosta A, Defaye P, et al. Arrhythmic cardiac arrest due to isolated coronary artery spasm: long-term outcome of seven resuscitated patients. J Am Coll Cardiol 1998; 31 (1): 57-61 (Pubitemid 28064722)
32. Krahn AD, Healey JS, Chauhan V, et al. Systematic assessment of patients with unexplained cardiac arrest. Circulation 2009; 120 (4): 278-85
33. Kido S, Ishii Y, Hasebe N, et al. Significance of coronary risk factors and coronary arteriosclerosis for coronary vasospasm. J Cardiol 1998; 31 (3): 135-43 (Pubitemid 28182570)
34. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation 1993; 87 (1): 76-9 (Pubitemid 23019336)
35. Conroy WG, Berg DK. Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions. J Biol Chem 1995; 270 (9): 4424-31
36. Sueda S, Kohno H, Fukuda H, et al. Clinical impact of selective spasm provocation tests: comparisons between acetylcholine and ergonovine in 1508 examinations. Coron Artery Dis 2004; 15 (8): 491-7
37. Geevasinga NM, Mahunt N. Call-Fleming syndrome associated with varenicline [online]. Available from URL: http://www.anzan2011.com/abstract/62. asp [Accessed 2011 Sep 1];
38. Niedermaier O, Smith M, Beightol L, et al. Influence of cigarette smoking on human autonomic function. Circulation 1993; 88 (2): 562-71 (Pubitemid 23228056)
39. Dunn FG. Hypertension and myocardial infarction. J Am Coll Cardiol 1983; 1 (2 Part 1): 528-32 (Pubitemid 13063208)
40. Madhavan S, Ooi W, Cohen H, et al. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23 (3): 395-401 (Pubitemid 24076725)
41. Cosentino F, Volpe M. Hypertension, stroke, and endothelium. Curr Hypertens Rep 2005; 7 (1): 68-71 (Pubitemid 40277792)
42. Moore C, Wang Y, Ramage AG. Cardiovascular effects of activation of central a7 and a4b2 nAChRs: a role for vasopressin in anaesthetized rats. Br J Pharmacol 2008; 153 (8): 1728-38 (Pubitemid 351545808)
43. Belluardo N, Mudò G, Blum M, et al. Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav Brain Res 2000; 113 (1-2): 21-34 (Pubitemid 30645540)
44. Gourine AV, Wood JD, Burnstock G. Purinergic signalling in autonomic control. Trends Neurosci 2009; 32 (5): 241-8
45. Dampney RA. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev 1994; 74 (2): 323-64 (Pubitemid 24127645)
46. Pilowsky PM, Goodchild AK. Baroreceptor reflex pathways and neurotransmitters: 10 years on. J Hypertens 2002; 20 (9): 1675-88
47. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci 2006; 7 (5): 335-46